英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

07630 英派药业-B

交易中 10-21 11:02:23

11.700

-0.530

-4.33%

最高12.710	最低11.700	成交量127.60万
今开12.460	昨收12.230	日振幅8.26%
总市值33.05亿	流通市值33.05亿	总股本2.82亿
成交额1,551万	换手率0.45%	流通股本2.82亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"英派药业-B","latestPrice":11.7,"timestamp":1792551741301,"preClose":12.23,"halted":0,"volume":1276000,"delay":0,"changeRate":-0.04333605887162724,"floatShares":282461530,"shares":282461530,"eps":-1.294715,"marketStatus":"交易中","change":-0.53,"latestTime":"10-21 11:02:23","open":12.46,"high":12.71,"low":11.7,"amount":15512314,"amplitude":0.082584,"askPrice":11.72,"askSize":5200,"bidPrice":11.69,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-1.052,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1792555200000},"marketStatusCode":2,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":12.23,"openAndCloseTimeList":[[1792546200000,1792555200000],[1792558800000,1792569600000]],"volumeRatio":1.366428,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/07630","defaultTab":"news","newsList":[{"id":"1181360178","title":"异动解读｜英派药业-B盘中上涨9.03%，塞纳帕利获CHMP积极意见持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1181360178","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181360178?lang=zh_cn&edition=full","pubTime":"2026-10-16 11:48","pubTimestamp":1792122536,"startTime":"0","endTime":"0","summary":"10月16日，英派药业-B盘中上涨9.03%，报14.12港元，成交额3870.87万港元。消息面上，公司核心产品塞纳帕利此前获得欧洲药品管理局人用药品委员会积极意见，建议批准其用于晚期上皮性卵巢癌、输卵管癌及原发性腹膜癌的一线维持治疗，后续将提交欧盟委员会作最终决定。此外，公司9月已纳入沪深港通，叠加上半年收入1.05亿元、同比增长316.8%，核心产品商业化与国际化进展共同支撑市场情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"塞纳帕利获CHMP积极意见，英派药业盘中上涨","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105965472","title":"异动解读｜英派药业-B盘中下跌8.07%，塞纳帕利获批利好兑现后资金获利了结","url":"https://stock-news.laohu8.com/highlight/detail?id=1105965472","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105965472?lang=zh_cn&edition=full","pubTime":"2026-10-08 14:05","pubTimestamp":1791439539,"startTime":"0","endTime":"0","summary":"10月8日，英派药业-B盘中下跌8.07%，报13.32港元，成交额2707.82万港元。尽管公司核心产品塞纳帕利近期获得欧洲药品管理局人用药品委员会积极意见，且该药已在国内纳入医保并实现快速放量，但股价在连续上涨后出现明显获利回吐压力。此前塞纳帕利国际化里程碑落地叠加港股通纳入，推动股价阶段性走强，部分资金选择在利好兑现后锁定收益。公司是一家处于商业化阶段的生物技术企业，核心产品塞纳帕利已在中国获批用于卵巢癌一线维持治疗，并持续推进欧洲等海外市场布局。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"塞纳帕利利好兑现，英派药业盘中下跌","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172946206","title":"英派药业-B9月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1172946206","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172946206?lang=zh_cn&edition=full","pubTime":"2026-10-05 16:39","pubTimestamp":1791189541,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司于2026年10月5日发布2026年9月股份变动月报。报告显示，截至2026年9月30日，公司法定注册股本及已发行股份数目均无变化，股本总体保持稳定。公告披露，公司的法定/注册股本为人民币282,461,530元，每股面值1元，截至9月末法定/注册股份总数为282,461,530股。本月内，此类普通H股无新增发行、无减发、无库藏股变动及注销情况。本次公告由执行董事兼首席执行官蔡遂雄签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174475215","title":"异动解读｜英派药业-B盘中上涨8.26%，塞纳帕利欧洲CHMP获批利好持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1174475215","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174475215?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:31","pubTimestamp":1790659912,"startTime":"0","endTime":"0","summary":"9月29日，英派药业-B盘中上涨8.26%，报14.03港元，成交额5400.01万港元，此前该股曾一度回调逾10%后企稳反弹。消息面上，公司核心产品塞纳帕利近期获欧洲药品管理局人用药品委员会积极意见，建议批准其用于晚期上皮性卵巢癌等维持治疗的上市许可，后续将提交欧盟委员会作出最终决定，一旦获批将可在所有欧盟成员国及欧洲经济区国家上市销售。此外，公司此前已与Pharmanovia达成独家授权协议，覆盖欧洲、中东、北非等地区，最高交易对价达4.235亿欧元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"塞纳帕利欧洲获批在望，英派药业上涨","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122893246","title":"异动解读｜英派药业-B盘中下跌8.05%，前期大涨后回调叠加生物科技板块整体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1122893246","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122893246?lang=zh_cn&edition=full","pubTime":"2026-09-24 10:12","pubTimestamp":1790215920,"startTime":"0","endTime":"0","summary":"9月24日，英派药业-B盘中下跌8.05%，报13.93港元，成交额3770.61万港元。该股此前因核心产品塞纳帕利获欧洲药品管理局（EMA）人用药品委员会（CHMP）积极意见，建议批准其用于晚期卵巢癌等维持治疗的上市许可，股价在9月21日单日大涨逾27%，盘中一度涨超40%至20.56港元，短期累计涨幅显著。经历快速拉升后，获利回吐压力加大。与此同时，生物科技板块整体承压，康方生物跌3.54%、荣昌生物跌5.71%、三生制药跌3.7%、信达生物跌3.53%，板块联动下行对个股形成拖累。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"英派药业涨后回调，生物科技板块走弱拖累","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669349171","title":"英派药业-B（07630）盘中拉升逾40% 药品Sepalna上市许可获欧洲CHMP建议批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2669349171","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669349171?lang=zh_cn&edition=full","pubTime":"2026-09-21 11:33","pubTimestamp":1789961630,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英派药业-B 盘中逆市拉升40.06%，暂报18.25港元，成交额3.25亿港元。消息面上，该公司发布公告，欧洲药品管理局人用药品委员会已通过了一项积极意见，建议批准药品Sepalna的上市许可，该药旨在用于晚期上皮性卵巢癌、输卵管癌及原发性腹膜癌的维持治疗。于CHMP建议批准后，塞纳帕利将提交至欧盟委员会作出最终决定。一旦获得欧盟委员会批准，塞纳帕利将获准在所有欧盟成员国及欧洲经济区国家上市销售。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992064","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IPOS","CHMP","07630","BK4087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669131578","title":"港股异动 | 英派药业-B(07630.HK)涨幅扩大逾41% 塞纳帕利国际化里程碑落地 公司入通有望持续吸引南下资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2669131578","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669131578?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:46","pubTimestamp":1789958791,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669136901","title":"英派药业-B盘初大涨逾22%，塞纳帕利获CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2669136901","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669136901?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:42","pubTimestamp":1789954959,"startTime":"0","endTime":"0","summary":"，英派药业-B发布公告，欧洲药品管理局（EMA）人用药品委员会（CHMP）已通过了一项积极意见，建议批准药品Sepalna®（塞纳帕利）的上市许可（MA），该药旨在用于晚期上皮性卵巢癌、输卵管癌及原发性腹膜癌的维持治疗。于CHMP建议批准后，塞纳帕利将提交至欧盟委员会（EC）作出最终决定。一旦获得欧盟委员会批准，塞纳帕利将获准在所有欧盟成员国及欧洲经济区国家上市销售。","market":"hk","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-21/doc-inispynh5991178.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["07630","BK4087","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669113660","title":"港股异动 | 英派药业-B(07630.HK)高开逾7% 塞纳帕利获CHMP积极意见 近期与Pharmanovia达成独家合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2669113660","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669113660?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:29","pubTimestamp":1789954177,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668292861","title":"重磅利好落地！塞纳帕利获欧洲药品管理局批准 英派药业-B (07630)收盘大涨15.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668292861","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668292861?lang=zh_cn&edition=full","pubTime":"2026-09-18 19:24","pubTimestamp":1789730648,"startTime":"0","endTime":"0","summary":"智通财经获悉，9月18日，创新药企英派药业-B走出明显拉升行情，全天收报13.03 港元，较前一交易日上涨 1.75 港元，涨幅15.51%。于CHMP建议批准后，塞纳帕利将提交至欧盟委员会作出最终决定。一旦获得欧盟委员会批准，塞纳帕利将获准在所有欧盟成员国及欧洲经济区国家上市销售。市场分析认为，创新药板块情绪修复叠加塞纳帕利欧洲药品管理局获批这一国际化里程碑落地，叠加港股通纳入、国内产品放量等多重利好，带动资金积极布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"重磅利好落地！塞纳帕利获欧洲药品管理局批准 英派药业-B (07630)收盘大涨15.51%","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668405459","title":"英派药业-B(07630.HK)：塞纳帕利获CHMP积极意见 有望用于晚期上皮性卵巢癌、输卵管癌及原发性腹膜癌的一线维持治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2668405459","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668405459?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:51","pubTimestamp":1789728715,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195688893","title":"英派药业-B（07630）PARP抑制剂塞纳帕利获EMA CHMP积极意见 迈向欧盟上市关键一步","url":"https://stock-news.laohu8.com/highlight/detail?id=1195688893","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195688893?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:51","pubTimestamp":1789728703,"startTime":"0","endTime":"0","summary":"2026年9月18日，英派药业-B发布自愿公告称，其自主研发的PARP1/2抑制剂塞纳帕利已获欧洲药品管理局人用药品委员会给出上市许可积极意见，用于晚期上皮性卵巢癌、输卵管癌及原发性腹膜癌患者的一线维持治疗。按照监管流程，相关申请将提交欧盟委员会作出最终决定；若获批准，塞纳帕利将可在全部欧盟成员国及欧洲经济区国家上市销售。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119221642","title":"英派药业-B：塞纳帕利提交欧盟委员会，等待最终上市许可裁决","url":"https://stock-news.laohu8.com/highlight/detail?id=1119221642","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119221642?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:49","pubTimestamp":1789728550,"startTime":"0","endTime":"0","summary":"英派药业-B宣布，其核心候选药物塞纳帕利已正式向欧洲委员会提交申请，寻求获得最终的上市授权决定。英派药业正积极推进塞纳帕利的国际化布局，此次提交是其在全球范围内拓展肿瘤治疗版图的重要里程碑。后者将据此做出具有法律约束力的最终审批决定，涵盖该药物在全部欧盟成员国的上市许可。塞纳帕利作为一种高选择性PARP抑制剂，被视为英派药业最具潜力的在研资产之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132852174","title":"英派药业与Pharmanovia宣布：Senaparib获欧洲药监局人用药品委员会积极意见，有望成为晚期高级别上皮性卵巢癌、输卵管癌及原发性腹膜癌的一线维持治疗新选择","url":"https://stock-news.laohu8.com/highlight/detail?id=1132852174","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132852174?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:40","pubTimestamp":1789728014,"startTime":"0","endTime":"0","summary":"英派药业与其合作伙伴Pharmanovia近日联合宣布，欧洲药品管理局人用药品委员会已对Senaparib——一种极具潜力的PARP抑制剂——发布积极审评意见。这一关键进展，为该药物作为晚期高级别上皮性卵巢癌、输卵管癌及原发性腹膜癌患者的一线维持治疗，铺平了道路。倘若一切顺利获批，Senaparib有望为这些侵袭性癌症亚型的患者群体提供一种全新的治疗范式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668191239","title":"港股午评|恒生指数早盘涨0.67%     AI制药板块大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2668191239","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668191239?lang=zh_cn&edition=full","pubTime":"2026-09-18 12:00","pubTimestamp":1789704004,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数涨0.67%，涨164点，报24768点；恒生科技指数涨1.74%。港股早盘成交1070亿港元。十部门印发医药十五五规划，机构看好医药迎“Claude”时刻。AI制药进入战略入局阶段。曦智科技-P涨超17%。天数智芯涨超13%，公司有望持续受益AI资本开支的增长及算力自主可控浪潮。MINIMAX-W涨13%，旗下多款产品通过Singtel AI Pass纳入配套订阅计划。俊知集团涨超10%，收购青海中利光纤技术有望打开AI算力相关光纤产品增量空间。大股东解禁期满。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348825331.USD","LU0128522157.USD","LU0862451753.SGD","03033","03032","02800","LU0572939691.SGD","LU1366334578.USD","LU0672654166.SGD","03696","BK1161","LU2242644610.SGD","LU1366334651.USD","BK1237","LU0561508036.HKD","TCHI","LU0862451837.USD","IE0003895053.USD","83115","01787","BK1583","09115","03419","BK1526","LU0029875118.USD","LU0244354667.USD","BK1149","02228","03088","300077","LU0890818403.SGD","LU1808992512.USD","LU0264606111.USD","LU0348827113.USD","09088","LU1267930227.SGD","LU0972618739.USD","02833","LU0791591158.USD","03417","LU1188198961.HKD","BK1163","HK0000306701.USD","LU0572940350.SGD","LU0048580855.USD","BK1193","600547","02670","07500","BK1197","LU0049112450.USD","LU1046422090.SGD","513600","BK1544","00992","02701","603127","LU0543330483.HKD","07226","02142","80992","BK1117","HSTECH","HSI","LU0791590937.USD","01879","HK0000320223.HKD","BK1576","LU0463099449.HKD","BK1183","02656","IE00B0JY6N72.USD","09067","06658","BK1617","IE0034224299.USD","MCHmain","LU1235295612.USD","LU0052756011.USD","LU0417516902.SGD","BK1574","BK1607","IE0032431581.USD","03115","09903","03067","00100","07300","LU0140636845.USD","07200","BK1141","07552","HK0000306685.HKD","LU1785774172.SGD","BK1592","BK1506","HK0000320264.USD","07630","06127","LU0320764755.SGD","HHImain","82800","LU0310800965.SGD","03423","LU1831875114.USD","BK1198","LU0181495838.USD","01818","03037","LNVGY","LU0326950275.SGD","LU0828237940.HKD","01300","07666","02837","LU0128525689.USD","LU0370786039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668911592","title":"英派药业-B早盘涨超20% 近期入通并获高管增持公司普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668911592","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668911592?lang=zh_cn&edition=full","pubTime":"2026-09-18 10:42","pubTimestamp":1789699320,"startTime":"0","endTime":"0","summary":"模拟交易客户端英派药业-B盘中涨超26%。截至发稿，股价上涨20.30%，现报13.57港元，成交额1.49亿港元。9月7日起，英派药业获纳入港股通名单。公司认为，获纳入沪港通及深港通将有利于进一步扩大公司的投资者基础，并有望提升公司H股的交易流动性。此外，公司执行董事兼首席执行官蔡遂雄近日于公开市场购买合共10万股公司普通股。塞纳帕利欧洲上市申请已获受理，预计2026年下半年获批。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-18/doc-inisfiik8576781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","07630","SURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668196969","title":"港股异动 | 英派药业-B(07630.HK)早盘涨超25% 近期入通并获高管增持 核心产品塞纳帕利加速放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2668196969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668196969?lang=zh_cn&edition=full","pubTime":"2026-09-18 10:01","pubTimestamp":1789696906,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667963143","title":"英派药业-B（07630）曾涨超20% 上周纳入港股通 中期营收增长超3倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2667963143","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667963143?lang=zh_cn&edition=full","pubTime":"2026-09-14 10:14","pubTimestamp":1789352048,"startTime":"0","endTime":"0","summary":"消息面上，公司H股已获纳入沪港通及深港通合资格证券名单，并自2026年9月7日起生效。根据此前英派药业公布的截至2026年6月30日止六个月中期业绩，期内收入达1.05亿元人民币，较去年同期的2520万元人民币大幅增长316.8%，主要来自核心产品塞纳帕利在中国的销售收入7040万元人民币及与Eikon Therapeutics合作协议的里程碑付款3480万元人民币。研发开支为9760万元人民币，主要用于塞纳帕利的欧洲药品管理局审查及早期候选药物的临床前研发。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991469","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","FLHK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544308","title":"港股异动 | 英派药业-B(07630.HK)尾盘涨超20% 公司本周进入港股通名单 塞纳帕利入医保后快速放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544308","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666544308?lang=zh_cn&edition=full","pubTime":"2026-09-11 15:31","pubTimestamp":1789111867,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665339957","title":"英派药业-B(07630)获纳入沪港通及深港通证券名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2665339957","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665339957?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:26","pubTimestamp":1788755188,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B(07630)发布公告，根据上海证券交易所及深圳证券交易所分别发出的公告，公司H股已获纳入沪港通及深港通合资格证券名单，自2026年9月7日起生效。公司H股获纳入沪港通及深港通合资格证券名单后，中国内地合资格投资者将可透过上海证券交易所及深圳证券交易所直接投资公司H股。公司认为，获纳入沪港通及深港通将有利于进一步扩大公司的投资者基础，并有望提升公司H股的交易流动性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","07630","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.impacttherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.0614},{"period":"3month","weight":0.0417},{"period":"6month","weight":-0.3915},{"period":"ytd","weight":-0.3915}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.0357},{"period":"3month","weight":-0.0412},{"period":"6month","weight":-0.079},{"period":"1year","weight":-0.077},{"period":"ytd","weight":-0.0688}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京英派药业股份有限公司是一家主要从事生物技术研发和商业化的中国公司。该公司处于商业化阶段。该公司致力于在全球范围内推进基于合成致死（SL）机制的精准抗癌疗法。该公司自主研发的核心产品塞纳帕利已在中国获批上市，作为卵巢癌（OC）一线维持疗法。该公司正在研发的产品管线包PARP1/2、PARP1、ATR、WEE1、PKMYT1/WEE1、DHX9、ATM、USP1及CHK1/2等。","exchange":"SEHK","name":"英派药业-B","nameEN":"IMPACT THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"英派药业-B,07630,英派药业-B股票,英派药业-B股票老虎,英派药业-B股票老虎国际,英派药业-B行情,英派药业-B股票行情,英派药业-B股价,英派药业-B股市,英派药业-B股票价格,英派药业-B股票交易,英派药业-B股票购买,英派药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}